Qureshi Danish J.
Known title: Chief Growth OfficerCIK: 0001864331
Associated companies
Transaction History
| LFST | ▼ Sell | Open Market | 150,000 | $782K | 6/14/2024 | View on chart |
| LFST | ▼ Sell | Open Market | 83,109 | $436K | 6/10/2024 | View on chart |
| LFST | ▼ Sell | Open Market | 12,965 | $77K | 4/1/2024 | View on chart |
| LFST | ▼ Sell | Open Market | 153,943 | $973K | 3/13/2024 | View on chart |
| LFST | ▲ Buy | Grant | 208,044 | $0 | 3/8/2024 | View on chart |
| LFST | ▲ Buy | Grant | 286,510 | $0 | 3/8/2024 | View on chart |
| LFST | ▼ Sell | Open Market | 71,811 | $648K | 6/21/2023 | View on chart |
| LFST | ▼ Sell | Open Market | 587 | $5K | 6/21/2023 | View on chart |
| LFST | ▼ Sell | Open Market | 8,775 | $67K | 4/4/2023 | View on chart |
| LFST | ▲ Buy | Grant | 320,512 | $0 | 3/6/2023 | View on chart |
| LFST | ▼ Sell | Open Market | 85,879 | $457K | 6/13/2022 | View on chart |
| LFST | ▲ Buy | Grant | 111,665 | $0 | 4/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Keybanc Raises LifeStance Health Price Target to $15
Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.
Keybanc Raises LifeStance Health Price Target to $15. Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.